News Column

Alexza Reports 2014 First Quarter Financial Results

May 19, 2014

By a News Reporter-Staff News Editor at Pharma Business Week -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported financial results for the quarter ended March 31, 2014. The net loss for the first quarter was $10.7 million compared to $20.7 million during the same quarter in 2013. At March 31, 2014, Alexza had consolidated cash, cash equivalents, marketable securities and restricted cash of $60.0 million (see also Alexza Pharmaceuticals, Inc.).

"We started 2014 with an impressive set of accomplishments," said Thomas B. King, President and CEO of Alexza. "The global launch of ADASUVE continues with additional product introductions in the United States, Spain, Romania and the Nordic countries. We also strengthened our balance sheet, as we completed a private placement to institutional investors of $45.0 million of non-recourse notes of our subsidiary."

King continued, "We have also strengthened our management, with the addition of Robert Lippe and Winston Brown to the Alexza management team. We look forward to their contributions to our progress through 2014 and beyond."

Keywords for this news article include: Alexza Pharmaceuticals Inc., Investment and Finance.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Pharma Business Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters